Tern SVV Fund undertakes its first investment

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has noted that following the agreement for Tern to participate in the new Sure Valley Ventures UK Software Technology Fund, announced on 2 March 2022, the new SVV Fund has undertaken its first investment.

The SVV Fund has led a ÂŁ2 million seed investment round, with the SVV Fund providing a ÂŁ1 million investment in RETìnĂ­ZE Limited, an award-winning creative-technology company based in Belfast, Northern Ireland.  RETìnĂ­ZE is developing an innovative software product, Animotive, that is harnessing virtual reality technologies to transform the 3D animation production process.  The investment is designed to drive RETìnĂ­ZE’s growth plan for the next two-years and the global rollout of Animotive.

Tern’s contribution to the SVV Fund’s investment in RETìnĂ­ZE will be covered by the approximately ÂŁ90,000 initially invested by Tern in the SVV Fund, as previously announced.

The SVV Fund are joined in RETìnĂ­ZE’s investment round by investors from the UK, USA, Ireland and the Netherlands, including: TechStart Ventures, who are following on from their 2019 pre-seed investment; VGC Partners; Clarendon/Co-fund NI; Lonely Horse Investments; Bertram van Munster and Elise Doganieri, the multi Emmy award-winning producers behind the CBS hit show ‘the Amazing Race’; and Ben Morrow, Senior Product Manager, Adobe Aero (Adobe’s AR creation tool).

RETìnĂ­ZE CEO, Phil Morrow, said: “We are thrilled to have Sure Valley on board as our lead investor – they have a deep knowledge of the creative tech sector and what impressed us most was the time they took to really understand and challenge our long-term goals and objectives.  This investment will supercharge our growth trajectory and will allow us to take Animotive to the international market.”

Sure Valley Ventures Principal, Isabelle O’Keeffe, said: “We are delighted to be able to support RETìnĂ­ZE as the first investment of our recently launched software fund, as it enters this exciting new phase. We recognise that the immersive software sector is poised for exponential growth, and the plans that RETìnĂ­ZE has for Animotive will position the company at the forefront of this expansion. We will continue to identify new opportunities in Metaverse, AI and Cybersecurity as we deploy our Fund II capital, with a focus on companies, like RETìnĂ­ZE, which are bringing a disruptive innovation to market.”

Commenting, Al Sisto, CEO of Tern said: “We are delighted to see the SVV Fund make their first investment.  In RETìnĂ­ZE they are investing in an exciting company developing innovative technology that fits very well with Tern’s existing participation in the virtual reality space. As a member of the SVV Fund’s Investor Committee, I look forward to working with RETìnĂ­ZE, with a view to benefiting both RETìnĂ­ZE and Tern’s wider network of companies.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search